AEONAEON Biopharma, Inc.

NYSE aeonbiopharma.com


$ 0.70 $ -0.03 (-4.96 %)    

Wednesday, 18-Sep-2024 15:42:10 EDT
QQQ $ 472.49 $ -2.05 (-0.43 %)
DIA $ 416.26 $ -1.07 (-0.26 %)
SPY $ 562.20 $ -1.67 (-0.3 %)
TLT $ 99.62 $ -1.25 (-1.24 %)
GLD $ 235.53 $ -1.83 (-0.77 %)
$ 0.67
$ 0.44 x 500
-- x --
-- - --
$ 0.67 - $ 17.17
121,569
na
26.48M
$ 0.20
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-12-2024 06-30-2024 10-Q
2 05-14-2024 03-31-2024 10-Q
3 03-29-2024 12-31-2023 10-K
4 11-13-2023 09-30-2023 10-Q
5 07-21-2023 06-30-2023 10-Q
6 05-17-2023 03-31-2023 10-Q
7 02-22-2023 12-31-2022 10-K
8 11-14-2022 09-30-2022 10-Q
9 08-12-2022 06-30-2022 10-Q
10 05-12-2022 03-31-2022 10-Q
11 03-28-2022 12-31-2021 10-K
12 11-15-2021 09-30-2021 10-Q
13 08-16-2021 06-30-2021 10-Q
14 06-15-2021 03-31-2021 10-Q
15 03-31-2021 12-31-2020 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 aeon-biopharma-files-for-class-a-common-stock-offering-of-up-to-50m

- SEC Filing

 hc-wainwright--co-maintains-buy-on-aeon-biopharma-lowers-price-target-to-5

HC Wainwright & Co. analyst Douglas Tsao maintains AEON Biopharma (AMEX:AEON) with a Buy and lowers the price target fro...

 aeon-biopharma-q2-2024-gaap-eps-422-may-not-compare-to-019-estimate

AEON Biopharma (AMEX:AEON) reported quarterly earnings of $4.22 per share which may not compare to estimate of $(0.19) by 2321....

 hc-wainwright--co-reiterates-buy-on-aeon-biopharma-maintains-6-price-target

HC Wainwright & Co. analyst Douglas Tsao reiterates AEON Biopharma (AMEX:AEON) with a Buy and maintains $6 price target.

 hc-wainwright--co-reiterates-buy-on-aeon-biopharma-maintains-6-price-target

HC Wainwright & Co. analyst Douglas Tsao reiterates AEON Biopharma (AMEX:AEON) with a Buy and maintains $6 price target.

 aeon-biopharma-announces-strategic-resource-reprioritization-and-cost-reduction-plan-aeon-has-reduced-its-workforce-by-55

AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a clinical-stage biopharmaceutical company focused ...

 hc-wainwright--co-maintains-buy-on-aeon-biopharma-lowers-price-target-to-6

HC Wainwright & Co. analyst Douglas Tsao maintains AEON Biopharma (AMEX:AEON) with a Buy and lowers the price target fro...

 aeon-biopharma-q1-2024-adj-eps-317-misses-031-estimate

AEON Biopharma (AMEX:AEON) reported quarterly losses of $(3.17) per share which missed the analyst consensus estimate of $(0.31...

 hc-wainwright--co-reiterates-buy-on-aeon-biopharma-maintains-18-price-target

HC Wainwright & Co. analyst Douglas Tsao reiterates AEON Biopharma (AMEX:AEON) with a Buy and maintains $18 price target.

 newly-listed-migraine-focused-aeon-biopharma-stock-plunges-on-friday---read-here-why

Preliminary results of AEON Biopharma's Phase 2 trial for chronic migraine treatment reveal no significant improvement over...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION